Last updated on April 16, 2014 at 17:34 EDT

Hovione´s Rapid Proof of Concept Dry Powder Inhalation Product Development

October 19, 2011

LOURES, Portugal, October 19, 2011 /PRNewswire/ –

Hovione today announced the launch of its Rapid Proof of Concept Study
for the development of dry powder inhalation (DPI) products.

Building on Hovione’s well established DPI development capability, the
new service simplifies the development of formulations, producing a proof of
concept formulation of a client’s molecule in just a few weeks.

Hovione has simplified DPI product development, reduced complexity and
reduced the time required for completion by mastering, in concert, particle
engineering, formulation technology and inhaler design, the three
disciplines vital to the development of a successful product. Unlike other
CROs, Hovione has all of this expertise under one roof, eliminating the
coordination issues clients often experience in having to use multiple CROs.
The results of this are reduced coordination costs, shortened development
timescales and a stream-lining of the development process.

Peter Villax, Hovione’s Vice President of Pharma & Innovation commented
“this new Rapid Proof of Concept service offers clients a low risk look at
the feasibility of developing a DPI product and gives clients greater
confidence about going into later stage development.” He added, “Clients of
the new service don’t just get a report, they get their first DPI

In a short period of time and for relatively little investment, a drug
developer can acquire a DPI formulation, potentially adding significant
value to an early stage out-licensing opportunity or helping a company move
into a stronger position in funding negotiations with venture capitalists.

About Hovione. Hovione is an international company with over 50 years’
experience in Active Pharmaceutical Ingredient development and compliant
manufacture. With four FDA inspected sites in the U.S., China, Ireland, and
Portugal, the company focuses on the most demanding customers, in the most
regulated markets. The company also offers integrated API, particle design
and formulation development and manufacturing. In the inhalation area,
Hovione is the only independent company offering such a broad range of

            Contacts at Hovione:
        Phil Nelson, PhD
        Business Development Manager

        Isabel Pina
        Marketing & Communication


SOURCE Hovione

Source: PR Newswire